Final frontier for meds? UK startup sends drug-making into space
BioOrbit, a UK startup, has launched its Box-E unit to the International Space Station to develop drug-crystallisation technology for cancer treatments. The technology aims to produce self-injected medications that patients can administer at home, reducing the need for hospital visits. This innovative approach could potentially save health systems millions by streamlining cancer treatment delivery.
- ▪BioOrbit's Box-E unit was launched from Kennedy Space Center to grow ultra-pure protein crystals in microgravity.
- ▪The technology aims to create self-injected cancer drugs that can be stored at home, improving patient convenience.
- ▪Dr Katie King, co-founder of BioOrbit, emphasizes that microgravity enhances the crystallisation process for protein drugs.
Opening excerpt (first ~120 words) tap to expand
BioOrbit’s Box-E unit was launched on a rocket from Kennedy Space Center heading for the International Space Station. Photograph: BioOrbitView image in fullscreenBioOrbit’s Box-E unit was launched on a rocket from Kennedy Space Center heading for the International Space Station. Photograph: BioOrbitPharmaceuticals industryFinal frontier for meds? UK startup sends drug-making into spaceBioOrbit hopes drug-crystallisation technology will lead to self-injected cancer treatment that could save millionsJulia KolleweSat 23 May 2026 05.00 EDTSharePrefer the Guardian on GoogleOnboard a SpaceX flight last week was a remarkable piece of cargo – a hi-tech box destined for the International Space Station to grow ultra-pure protein crystals, with the aim of producing self-injected cancer drugs.A…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Guardian — Tech.
Discussion
0 commentsMore from The Guardian — Tech
